Dicato M A
Centre Hospitalier de Luxembourg.
Eur J Cancer. 1991;27 Suppl 1:S18-9; discussion S22.
The efficacy and tolerability of twice-daily oral ondansetron treatment, after a single i.v. dose prechemotherapy, was compared with the established three times a day oral supplement regimen for the prophylaxis of nausea and vomiting induced by cyclophosphamide (greater than or equal to 500 mg/m2) in combination with doxorubicin (greater than or equal to 40 mg/m2) or epirubicin (greater than or equal to 40 mg/m2). Additional treatment with ondansetron twice daily or three times daily was equally effective in controlling emesis and nausea. Supplementary twice-daily oral treatment prevented emesis in 73% of patients in the first 24 h and in 65% of patients over 3 days. Both dose schedules were safe and well tolerated. Ondansetron given i.v. before chemotherapy followed by twice-daily (12-hourly) oral dosing has good efficacy in the control of emesis in oncology outpatients.
在化疗前单次静脉注射一剂昂丹司琼后，比较每日两次口服昂丹司琼治疗方案与既定的每日三次口服补充方案预防环磷酰胺（≥500mg/m²）联合多柔比星（≥40mg/m²）或表柔比星（≥40mg/m²）所致恶心和呕吐的疗效及耐受性。每日两次或三次额外给予昂丹司琼在控制呕吐和恶心方面同样有效。补充每日两次口服治疗在最初24小时内预防了73%患者的呕吐，在3天内预防了65%患者的呕吐。两种给药方案均安全且耐受性良好。化疗前静脉注射昂丹司琼，随后每日两次（每12小时一次）口服给药，在控制肿瘤门诊患者呕吐方面有良好疗效。
